Used to classify article posts by terms used for medical conditions. It’s mostly aimed at practitioners and physicians.

Cannabinoids, the Heart of the Matter.

Authors: Naghum Alfulaij, Franziska Meiners, Justin Michalek, Andrea L. Small‐Howard, et al
Journal of the American Heart Association, 13 July 2018

Cardiovascular disease (CVD) is a global epidemic representing the leading cause of death in some Western countries. According to the American Heart Association, a total of 92.1 million US citizens currently have ≥1 forms of CVD, with numbers expected to grow reaching up to 4…

Marijuana intoxication in a cat.

Authors: Agnieszka Janeczek, Marcin Zawadzki, Pawel Szpot, Artur Niedzwiedz
Acta Veterinaria Scandinavica, 11 July 2018

BACKGROUND: Cannabis from hemp (Cannabis sativa and C. indica) is one of the most common illegal drugs used by drug abusers. Indian cannabis contains around 70 alkaloids, and delta-9-tetrahydrocannabinol (delta-9-THC) is the most psychoactive substance. Animal intoxications oc…

Marijuana use and short-term outcomes in patients hospitalized for acute myocardial infarction.

Authors: Cecelia P. Johnson-Sasso, Christine Tompkins, David P. Kao, Lori A. Walker
PLoS One, 11 July 2018

Marijuana use is increasing worldwide, and it is ever more likely that patients presenting with acute myocardial infarctions (AMI) will be marijuana users. However, little is known about the impact of marijuana use on short-term outcomes following AMI. Accordingly, we compared…

Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence.

Authors: Emily Stockings, Dino Zagic, Gabrielle Campbell, Megan Weier, Wayne D Hall, et al
Journal of Neurology, Neurosurgery & Psychiatry, July 2018

Review evidence for cannabinoids as adjunctive treatments for treatment-resistant epilepsy. Systematic search of Medline, Embase and PsycINFO was conducted in October 2017. Outcomes were: 50%+ seizure reduction, complete seizure freedom; improved quality of life (QoL). Tolerab…

Marijuana Use in Adults Living with Sickle Cell Disease.

Authors: John D. Roberts, Jonathan Spodick, Joanna Cole, Janis Bozzo, Susanna Curtis, Ariadna Forray
Cannabis and Cannabinoid Research, July 2018

Introduction: Legal access to marijuana, most frequently as “medical marijuana,” is becoming more common in the United States, but most states do not specify sickle cell disease as a qualifying condition. We were aware that some of our patients living with sickle cell disease…

Self-initiated use of topical cannabidiol oil for epidermolysis bullosa.

Authors: Malcolm P. Chelliah, Zachary Zinn, Phoung Khuu, Joyce M. C. Teng
Pediatric Dermatology, July 2018

Epidermolysis bullosa is a rare blistering skin disorder that is challenging to manage because skin fragility and repeated wound healing cause itching, pain, limited mobility, and recurrent infections. Cannabidiol, an active cannabinoid found in cannabis, is postulated to have…

Pharmacokinetics of cannabidiol administered by 3 delivery methods at 2 different dosages to healthy dogs.

Authors: Lisa R. Bartner, Stephanie McGrath, Sangeeta Rao, Linda K. Hyatt, Luke A. Wittenburg
Canadian Journal of Veterinary Research, July 2018

The purpose of this study was to determine the pharmacokinetics of cannabidiol (CBD) in healthy dogs. Thirty, healthy research dogs were assigned to receive 1 of 3 formulations (oral microencapsulated oil beads, oral CBD-infused oil, or CBD-infused transdermal cream), at a dos…

Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs.

Authors: Lauri-Jo Gamble1, Jordyn M. Boesch, Christopher W. Frye, Wayne S. Schwark, Sabine Mann, Lisa Wolfe, Holly Brown, Erin S. Berthelsen, Joseph J. Wakshlag
Frontiers in Veterinary Science, July 2018

Objectives: The objectives of this study were to determine basic oral pharmacokinetics, and assess safety and analgesic efficacy of a cannabidiol (CBD) based oil in dogs with osteoarthritis (OA). Methods: Single-dose pharmacokinetics was performed using two different doses of…

Cannabis and Heart Disease: Forward Into the Great Unknown?

Authors: Joshua D. Lee, Daniel Schatz, Judith Hochman
Journal of the American College of Cardiology, 5 June 2018

The paper by DeFilippis et al. (1) in this issue of the Journal is a timely reminder of how little we know about cannabis consumption, cardiovascular disease (CVD), and cannabis’ health effects in general. It is also a firm confirmation of the negative effects of any cocaine u…

Cocaine and Marijuana Use Among Young Adults With Myocardial Infarction.

Authors: Ersilia M. DeFilippis, Avinainder Singh, Sanjay Divakaran, Ankur Gupta, Bradley L. Collins, et al
Journal of the American College of Cardiology, 5 June 2018

BACKGROUND: Substance abuse is increasingly prevalent among young adults, but data on cardiovascular outcomes remain limited. OBJECTIVES: The objectives of this study were to assess the prevalence of cocaine and marijuana use in adults with their first myocardial infarction (M…

Marijuana use during and after pregnancy and association of prenatal use on birth outcomes: A population-based study.

Authors: Jean Y. Ko, Van T. Tong, Jennifer M. Bombard, Donald K. Hayes, John Davy, et al
Drug and Alcohol Dependence, June 2018

BACKGROUND: We sought to describe the correlates of marijuana use during and after pregnancy, and to examine the independent relationship between prenatal marijuana use and infant outcomes. STUDY DESIGN: We used state-specific data from the Pregnancy Risk Assessment Monitoring…

Dangerous plants in dermatology: Legal and controlled.

Authors: Deeptej Singh, Juliya Fisher, Devorah Shagalov, Aakaash Varma, Daniel M. Siegel
Clinics in Dermatology, May-June 2018

The plant and mushroom kingdoms have species used for intoxication, inebriation, or recreation. Some of these species are toxic. Given that many of these plants or substances are illegal and have histories of abuse, much of the research regarding therapeutic application is bas…